72 Hammersmith Road
16 articles with Avillion
Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.
Sanofi, AstraZeneca, Avillion and Diadem recently announced clinical results, providing positive news for patients with multiple myeloma, asthma and Alzheimer’s disease.
PT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide, Used as an As-Needed Rescue Medicine, Significantly Reduced the Risk of a Severe Exacerbation Compared to Albuterol by 27% in Patients With Asthma
Full results from the positive MANDALA Phase III trial showed that PT027 at two different strengths of budesonide, an inhaled corticosteroid, used as an as-needed rescue medicine, demonstrated a statistically significant reduction in the risk of a severe exacerbation versus albuterol rescue in patients with moderate to severe asthma.
Avillion Appoints Dr Anders Gersel Pedersen, M.D., Ph.D. as Board Member
Avillion LLP announces the appointment of Dr Anders Gersel Pedersen as a Non-Executive Director of Bond 2 Development 2 GP, the General Partner of Bond Avillion 2, the Avillion entity that enters into the co-development agreements with pharma partners.
Avillion Advances Co-Development Programme With Merck: IND Now Open for Phase II Study of M1095, an Anti-IL-17 A/F Nanobody in Psoriasis
Avillion is focused on this collaborative approach to advancing the development of late-stage clinical candidates for pharmaceutical company partners.
Avillion Announces U.S. Approval of Pfizer's BOSULIF (bosutinib) for the Treatment of Patients With Newly-Diagnosed Ph+ CML
Avillion announces that the FDA today approved a supplemental sNDA for Pfizer's BOSULIF (bosutinib).
Avillion Appoints Kathryn J. Gregory As Chief Business Officer
Avillion And Pfizer Release: FDA And EMA Accept Regulatory Submissions For BOSULIF® (Bosutinib) For The Treatment Of Patients With Newly Diagnosed Ph+ Chronic Myeloid Leukemia
Merck KGaA, Darmstadt, Germany Advances R&D Strategy Through Unique Development Model With Avillion For Anti IL-17 A/F Nanobody
Avillion Signs Clinical Co-Development Agreement With Merck & Co. To Advance Anti IL-17 A/F Nanobody In Psoriasis
Avillion Release: Company Strengthens Clinical And Regulatory Development Capabilities With The Appointment Of Mark Weinberg As Chief Medical Officer
Pfizer And Avillion Announce Positive Top-Line Results For Phase III BFORE Study Of BOSULIF For First-Line Treatment Of Philadelphia Chromosome Positive Chronic Myeloid Leukemia
Avillion Announces Completion Of Enrolment In Phase III BFORE Trial To Assess BOSULIF (bosutinib) As First-Line Treatment For Patients With Chronic Myelogenous Leukemia
Avillion Appoints Jarrod Longcor As Chief Business Officer
Avillion Announces Dosing Of First Patients In Phase 3 BFORE Trial To Assess BOSULIF® (bosutinib) As First-Line Treatment For Patients With Chronic Myelogenous Leukemia
Avillion Appoints Dr. Allison Jeynes-Ellis As Chief Executive Officer